SCHEMBL5124266

SCHEMBL5124266

Cc1csc2nc(-n3cncn3)nc(NCCc3ccc4c(c3)OCO4)c12

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BCDIN3D Q7Z5W3 1/20 0.42
NOS2 P35228 3/20 0.39
PDE5A O76074 2/20 0.39
FLT1 P17948 3/20 0.37
KDR P35968 3/20 0.37
IDO1 P14902 1/20 0.37
NOS1 P29475 1/20 0.36
ALDH1A1 P00352 3/20 0.36
TSHR P16473 2/20 0.36
NPSR1 Q6W5P4 2/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
TP53 P04637 1/20 0.36
MAPT P10636 1/20 0.36
HTT P42858 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
USP2 O75604 1/20 0.34
HPGD P15428 1/20 0.34
ALOX15 P16050 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5121170 0.91 TSHR (0.44) PDE5AFLT1KDRALDH1A1TSHR
SCHEMBL5128666 0.86 BCDIN3D (0.42) BCDIN3DNOS2PDE5AFLT1KDR
SCHEMBL5128237 0.86 BCDIN3D (0.41) BCDIN3DNOS2PDE5AFLT1KDR
SCHEMBL5127699 0.86 CHRM4 (0.42) NOS2PDE5ANOS1ALDH1A1TSHR
SCHEMBL5122969 0.85 NOS2 (0.54) NOS2NOS1
SCHEMBL5124141 0.85 BCDIN3D (0.41) BCDIN3DNOS2PDE5AFLT1KDR
SCHEMBL5122862 0.84 BCDIN3D (0.45) BCDIN3DNOS2PDE5AFLT1KDR
SCHEMBL7615720 0.84 BCDIN3D (0.45) BCDIN3DNOS2PDE5AFLT1KDR
SCHEMBL5777505 0.83 ALDH1A1 (0.44) BCDIN3DALDH1A1TSHRNPSR1KMT2A
SCHEMBL5116184 0.82 BCDIN3D (0.45) BCDIN3DNOS2PDE5AFLT1KDR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20080045529-A1 Use Of Thienopyrimidines MERCK PATENT GMBH (DE) 2008-02-21 US disclosed
EP-1685136-A1 USE OF THIENOPYRIMIDINES MERCK PATENT GmbH (DE) 2006-08-02 EP disclosed
WO-2005047292-A1 USE OF THIENOPYRIMIDINES MERCK PATENT GMBH (DE) 2005-05-26 WO disclosed
US-6432950-B1 ANTICANCER AGENTS; KILLING CANCER CELLS CELL PATHWAYS 2002-08-13 US disclosed
US-6133271-A Method for inhibiting neoplastic cells and related conditions by exposure thienopyrimidine derivatives CELL PATHWAYS, INC. (US) 2000-10-17 US disclosed
US-6110920-A TREATMENT OF CARDIOVASCULAR DISORDERS AND IMPOTENCY MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) 2000-08-29 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080045529-A1 Use Of Thienopyrimidines TIE1, DPYD, TK2 BCDIN3D 1161/4885NOS2 724/4885PDE5A 2002/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.